BRCA1/2 mutation non-carriers with HRD features can also benefit from PARP inhibitors, [118, 121, 141] thus, a major challenge has been to identify HRD tumors beyond gBRCAm. The gene discussed is PARP1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.